Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

SIMPLE SUMMARY: Poly ADP-ribose polymerase inhibitors (PARPis) can be used in men with advanced prostate cancer. Unfortunately, this class of therapeutics has demonstrated the risk of developing hematological adverse events. We conducted a systematic review and meta-analysis of several PARPi clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowling, Gartrell C., Swargaloganathan, Piragash, Heintz, Carly, Madan, Ravi A., Eldhose, Binil, Dobi, Albert, Chesnut, Gregory T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571760/
https://www.ncbi.nlm.nih.gov/pubmed/37835597
http://dx.doi.org/10.3390/cancers15194904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571760/
https://www.ncbi.nlm.nih.gov/pubmed/37835597
http://dx.doi.org/10.3390/cancers15194904

Ejemplares similares